Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC1 | P19801 | 2/20 | 0.32 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KDM6B | O15054 | 1/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955988 | 0.83 | — | — | |
| SCHEMBL2221297 | 0.78 | MAPT (0.43) | AOC1AOC3MEN1ALDH1A1MAPT | |
| SCHEMBL2263390 | 0.75 | TDO2 (0.47) | CDK2PRKCZKDM4EMEN1ALDH1A1 | |
| SCHEMBL2219633 | 0.73 | CYP2A6 (0.52) | KDM4EMEN1ALDH1A1MAPT | |
| SCHEMBL15301520 | 0.73 | CYP11B2 (0.39) | — | |
| SCHEMBL17555456 | 0.72 | ALDH1A1 (0.42) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15301806 | 0.72 | CYP2A6 (0.50) | — | |
| SCHEMBL18476225 | 0.72 | PPARA (0.31) | — | |
| SCHEMBL15301581 | 0.72 | TDO2 (0.50) | KDM4EMEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL15301561 | 0.72 | CYP1A2 (0.41) | CDK2PRKCZMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BIOSPLICE THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | MED-PATHWAYS II LIMITED (VG) | 2024-04-11 | — | — | US | disclosed |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | BIOSPLICE THERAPEUTICS, INC. (US) | 2023-07-11 | — | — | US | disclosed |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3915988-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | BioSplice Therapeutics, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020150545-A1 | PYRAZOLE DERIVATIVES AS MODULATORS OF THE WNT/B-CATENIN SIGNALING PATHWAY | SAMUMED, LLC (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | TENARX, INC. | 2020-06-18 | — | — | US | disclosed |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC | 2020-05-21 | — | — | US | disclosed |
| US-10407425-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-09-10 | — | — | US | disclosed |
| WO-2013166396-A2 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-11-07 | — | — | WO | disclosed |
| US-20130296302-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2013-11-07 | — | — | US | disclosed |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | US | disclosed |
| WO-2013151708-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | SAMUMED, LLC (US) | 2013-08-29 | — | — | US | disclosed |
| US-8450340-B2 | 1H-pyrazolo[3,4-b]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2515655-A1 | 1H-PYRAZOLO[3,4-BETA]PYRIDINES AND THERAPEUTIC USES THEREOF | Samumed, LLC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-08-04 | — | — | US | disclosed |
| WO-2011084486-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | EPITHERIX, LLC (US) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947228-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
| US-20110190290-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | AOC1 1372/4885AOC3 810/4885CDK2 885/4885 |
| US-20130225576-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | AOC1 1372/4885AOC3 810/4885CDK2 885/4885 |
| US-11697649-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
| US-20230013144-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
| US-20130296302-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | AOC1 1338/4885AOC3 436/4885CDK2 372/4885 |
| US-20240116927-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
| US-20200190082-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
| US-10407425-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
| US-20260116878-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | AOC1 4355/4885AOC3 2312/4885CDK2 463/4885 |
| US-20130296307-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | BRCA1, THPO, PDXK | AOC1 1372/4885AOC3 810/4885CDK2 885/4885 |
| US-20200155525-A1 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF | COL1A1, NOX4, FGF1 | AOC1 1338/4885AOC3 436/4885CDK2 372/4885 |
| US-20130267495-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | AOC1 4800/4885AOC3 3362/4885CDK2 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.